Glycomimetics Shares Fall After Leukemia Treatment Trial Misses Key Goal

Dow Jones10-29

By Adriano Marchese

Glycomimetics shares fell in premarket trading after the company said a trial for cancer treatment Uproleselan missed its primary target.

Shares fell 6.7% to 16 cents.

The Rockville, Maryland-based clinical-stage biotechnology company said the Phase 2 study didn't show a statistically significant improvement for patients receiving the drug in combination with chemotherapy versus chemotherapy alone.

The study was performed on adults with newly diagnosed acute myeloid leukemia who were 60 years or older and fit for intensive chemotherapy.

Acute myeloid leukemia is form of blood cancer which grows abnormal cells rapidly, building up in the bone marrow and blood, and interfering with normal blood cell production.

Glycomimetics said it will transfer the trial data to the National Cancer Institute and the Alliance for Clinical Trials in Oncology to determine if the treatment may merit further study in future clinical trials.

Write to Adriano Marchese at adriano.marchese@wsj.com

(END) Dow Jones Newswires

October 29, 2024 07:01 ET (11:01 GMT)

Copyright (c) 2024 Dow Jones & Company, Inc.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2479477618?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-10-29 19:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2479477618","market":"hk","top_or_hot":-1,"title":"Glycomimetics Shares Fall After Leukemia Treatment Trial Misses Key Goal","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Adriano Marchese \n</p>\n<pre>\n \n</pre>\n<p>\n  Glycomimetics shares fell in premarket trading after the company said a trial for cancer treatment Uproleselan missed its primary target. \n</p>\n<p>\n  Shares fell 6.7% to 16 cents. \n</p>\n<p>\n  The Rockville, Maryland-based clinical-stage biotechnology company said the Phase 2 study didn't show a statistically significant improvement for patients receiving the drug in combination with chemotherapy versus chemotherapy alone. \n</p>\n<p>\n  The study was performed on adults with newly diagnosed acute myeloid leukemia who were 60 years or older and fit for intensive chemotherapy. \n</p>\n<p>\n  Acute myeloid leukemia is form of blood cancer which grows abnormal cells rapidly, building up in the bone marrow and blood, and interfering with normal blood cell production. \n</p>\n<p>\n  Glycomimetics said it will transfer the trial data to the National Cancer Institute and the Alliance for Clinical Trials in Oncology to determine if the treatment may merit further study in future clinical trials. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Adriano Marchese at adriano.marchese@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  October 29, 2024 07:01 ET (11:01 GMT)\n</p>\n<p>\n  Copyright (c) 2024 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Glycomimetics Shares Fall After Leukemia Treatment Trial Misses Key Goal</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGlycomimetics Shares Fall After Leukemia Treatment Trial Misses Key Goal\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-10-29 19:01 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://dowjonesnews.com/newdjn/logon.aspx?AL=N><strong>Dow Jones</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>By Adriano Marchese \n\n\n \n\n\n  Glycomimetics shares fell in premarket trading after the company said a trial for cancer treatment Uproleselan missed its primary target. \n\n\n  Shares fell 6.7% to 16 cents...</p>\n\n<a href=\"https://dowjonesnews.com/newdjn/logon.aspx?AL=N\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"GLYC","symbol_name":"GlycoMimetics Inc.","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2479477618","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2479477618","pubTimestamp":1730199660,"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Glycomimetics shares fell in premarket trading after the company said a trial for cancer treatment Uproleselan missed its primary target.The Rockville, Maryland-based clinical-stage biotechnology company said the Phase 2 study didn't show a statistically significant improvement for patients receiving the drug in combination with chemotherapy versus chemotherapy alone.The study was performed on adults with newly diagnosed acute myeloid leukemia who were 60 years or older and fit for intensive chemotherapy.Acute myeloid leukemia is form of blood cancer which grows abnormal cells rapidly, building up in the bone marrow and blood, and interfering with normal blood cell production.Glycomimetics said it will transfer the trial data to the National Cancer Institute and the Alliance for Clinical Trials in Oncology to determine if the treatment may merit further study in future clinical trials.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"GLYC":"GlycoMimetics Inc.","BK4139":"生物科技"},"translate_title":"白血病治疗试验未能实现关键目标后，拟糖药股价下跌","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"GLYC":1},"content_text":"By Adriano Marchese \n\n\n \n\n\n  Glycomimetics shares fell in premarket trading after the company said a trial for cancer treatment Uproleselan missed its primary target. \n\n\n  Shares fell 6.7% to 16 cents. \n\n\n  The Rockville, Maryland-based clinical-stage biotechnology company said the Phase 2 study didn't show a statistically significant improvement for patients receiving the drug in combination with chemotherapy versus chemotherapy alone. \n\n\n  The study was performed on adults with newly diagnosed acute myeloid leukemia who were 60 years or older and fit for intensive chemotherapy. \n\n\n  Acute myeloid leukemia is form of blood cancer which grows abnormal cells rapidly, building up in the bone marrow and blood, and interfering with normal blood cell production. \n\n\n  Glycomimetics said it will transfer the trial data to the National Cancer Institute and the Alliance for Clinical Trials in Oncology to determine if the treatment may merit further study in future clinical trials. \n\n\n \n\n\n  Write to Adriano Marchese at adriano.marchese@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  October 29, 2024 07:01 ET (11:01 GMT)\n\n\n  Copyright (c) 2024 Dow Jones & Company, Inc.","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.2","shortVersion":"4.29.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2479477618"}